Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: CSBR

Champions Oncology, Inc.

Healthcare | Biotechnology

No licensed closing price on file for CSBR. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-0.08

Champions Oncology, Inc. (NASDAQ: CSBR) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 09:13 UTC.

What Champions Oncology, Inc. does

The company is a technology-enabled research organization that creates computational and experimental platforms to support drug discovery and development, primarily in oncology. At the center of its operations is a proprietary bank of patient-derived xenograft models maintained in mice, which is characterized extensively at molecular, phenotypic, and pharmacological levels.

Summarized from Champions Oncology, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-0.08

Revenue, margins & earnings

FY2022 Net income: $548,000FY2022 Operating costs: $49M$49MFY2022FY2023: net loss $5M on revenue $54M$54MFY2023FY2024: net loss $7M on revenue $50M$50MFY2024FY2025 Revenue: $57M — margin split not shown (non-operating gains)$57MFY2025FY2026: net loss $1M on revenue $59M$59MFY2026
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-16
  • 2026-10-16DirectorOption exercise69,794$111.7K
  • 2026-10-16DirectorOption to purchase Common StockOption exercise-69,794$111.7K
  • 2026-01-30DirectorOption to purchase Common StockAward14,130$98.9K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Champions Oncology, Inc. do?

The company is a technology-enabled research organization that creates computational and experimental platforms to support drug discovery and development, primarily in oncology.

When did CSBR last file with the SEC?

Champions Oncology, Inc.'s most recent SEC filing on record is a 8-K filed 2026-03-30. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 09:13 UTC. This page is also available as JSON at /api/data?ticker=CSBR and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for CSBR and 5,000+ tickers.

Create a free account — keep CSBR
For your agent
GET /api/data?ticker=CSBR

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt